Eli Lilly also said it has filed for Food and Drug Administration approval of the daily GLP-1 pill, called orforglipron, for ...

Eli Lilly (LLY) stock is in focus as the company posts late-stage trial data to indicate that its obesity pill orforglipron ...

Eli Lilly's obesity pill helped patients maintain weight loss after they switched from injectable drugs, outcomes that could ...

Eli Lilly is slashing the prices of its popular diabetes and weight-loss drugs Mounjaro and Zepbound by 20% or more in Canada ...

Eli Lilly said on Thursday its next-generation obesity drug helped patients lose an average of 28.7% of their weight in a ...

Eli Lilly said it has lowered the price of single-dose vials of its popular obesity drug Zepbound to make the treatment more ...

Eli Lilly is leading the market for GLP-1 medications (for weight loss and diabetes). In a decade, Eli Lilly could be in the ...

Lilly's Zepbound price cuts ranged from $50 to $100, depending on the dosage, for consumers who pay cash via the drugmaker's ...

Weight-loss drugs have exploded in popularity, so FOX59 NOW is taking a closer look into how they impact our bodies. “For so long we thought obesity was a personal choice, — ...

The maker of Zepbound reported results from a study of retatrutide, which targets three hormones in the body and led to much more weight loss than any approved drug.

Eli Lilly's experimental drug, retatrutide, showed strong results in a late-stage trial, helping patients lose nearly 29% of ...

Discover why Eli Lilly's stock downturn may present new opportunities. Learn about valuation, Zepbound pricing, and 2026 ...